[Clinical pharmacokinetic study of cisplatin in enhancing cervical cancer radiosensitivity].
To evaluate the pharmacokinetics of cisplatin in enhancing the radiosensitivity of stage IIa-IIb bulky cervical cancer. Thirty-six patients with stage IIa-IIb bulky cervical cancer were treated intravenously with cisplatin (30 mg/m(2)) and cisplatin levels were measured in tumor tissues and serum of the patients at the random time points of 1, 2, 4, 6, 10, 18, and 24 h following the injection. Cisplatin levels were also measured in the tissues following administration of different radiation doses by flameless atomic absorption spectrometry. Cisplatin level in the tumor tissues was the highest at 4 h following the injection, and its serum level showed obvious reduction within 2 h following the injection. Radiation increased cisplatin level in the tumor tissue. Cisplatin level reaches the highest level in the cancer tissue at 4 h following intravenous injection, a time when cisplatin can best execute its effect in enhancing the radiosensitivity of cervical cancer, and cisplatin administration in later stage of radiotherapy may achieve better effect than early stage administration.